CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 120 enrolled
Drug / intervention
Double Stimulation (Elonva+rFSH) in luteal /follicular phase +1 moredrug
Likely dose
Double Stimulation (Elonva+rFSH) in luteal /follicular phase 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04446845
NCT04446845Phase 4Completed

Double vs. Single Stimulation in Young Poor Prognosis Patients Followed by a Fresh Embryo Transfer. A Randomized Clinical Trial

Fundación Santiago Dexeus Font·interventional·Posted Jun 25, 2020·Updated May 15, 2023

In Brief

A Phase 4 clinical trial evaluating Double Stimulation (Elonva+rFSH) in luteal /follicular phase and Conventional Stimulation (Elonva+rFSH) in follicular phase for Infertility. Completed, enrolled 120 participants across 1 site.

Detailed Summary

The major goal of controlled ovarian stimulation (COS) is to increase the number of oocytes harvested in order to result in the generation of a higher number of available embryos, extended embryo culture, embryo selection and finally providing higher cumulative live birth rates in infertile patients. Moreover, with the idea of the multiple waves of follicular production, we could start to take full advantage of the whole follicular cohort, and not only of the follicular wave. In the context of low prognosis women such as women with poor ovarian response where, the success rates are very low due to the low number of oocytes retrieved and consequently of viable embryos), Dual stimulation may be of great value as a tool to improve outcomes. The reported advantage of DuoStim is retrieved of more oocytes within a shorter time span, resulting in an increase in the probability of having transferable embryos increases, and theoretically reducing time to live birth as well as cycle cancellation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility
CountriesSpain

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJun 25, 2020
Enrollment StartOct 30, 2020
Primary CompletionJan 15, 2023
Study CompletionMay 2, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.0 years ago

Interventions

Double Stimulation (Elonva+rFSH) in luteal /follicular phasedrug

Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.

Conventional Stimulation (Elonva+rFSH) in follicular phasedrug

From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.